Study examines increased physical activity may lower the risk for several cancers and may be beneficial for improving quality of life.
A CHEST expert panel has released updated guidelines for lung cancer screening.
Patients who underwent lung resections had reduced postoperative complication rates when they participated in preoperative exercise.
Mortality rates are higher after surgery vs stereotactic body radiotherapy for patients with early non-small-cell lung cancer.
Lung cancer screening is more effective and efficient for high-risk individuals.
Younger age and higher body mass index may be positive predictors of progression-free survival in patients with squamous cell carcinoma of the lung.
Lack of insurance correlated with a reduced likelihood of chemotherapy and radiation therapy for small cell lung cancer.
Qualitative risk statements of malignancy for indeterminate pulmonary nodules are imprecise, highly variable, and should be replaced by a standard scale.
The cancer death rate declined by 1.5% annually from 2006 to 2015 in the United States.
Lung cancer screening based on USPSTF criteria decreased from 2010 to 2015 while risk-targeted screening is associated with modest gains in terms of early lung cancer mortality per person screened.
Few modern, US FDA-approved immuno-oncology agents have durable survival and response rates that are deemed significant by the ASCO value framework.
Many octogenarians and nonagenarians with non-small cell lung cancer do not receive cancer-directed care.
Platinum-based chemotherapy agents for lung cancer may increase the risk for thromboembolism.
Adjuvant chemotherapy administered prior to, rather than concurrently with, radiotherapy improves survival outcomes among patients with NSCLC.
Few cases of lung cancer suspected in counties with smoke-free ordinances.
Improvements in cancer survival were limited to patients with private insurance, from 1997-2014.
An estimated 42.0% of all incident cancers and 45.1% of cancer deaths in the United States are attributed to potentially modifiable risk factors.
Survival is better with lobectomy than SBRT in patients with NSCLC.
Three of 13 attributes identified had the highest potential for reduced spending without compromising care.
More than 50% of patients report experiencing cancer-related fatigue throughout the disease process.
Patients with PD-L1-positive malignancies have shown higher response rates to immune checkpoint inhibition and consequently prolonged progression-free/overall survival compared with others.
Treatment with osimertinib is associated with longer progression-free survival in patients with previously untreated EGFR mutation-positive advanced non-small-cell lung cancer.
Between 2000 and 2010, researchers identified a decline in the number of patients with stage I NSCLC who remained untreated.
Results of two phase 3 studies found that nivolumab provided superior overall survival vs docetaxel in people with non-small cell lung cancer.
Trial results provided strong evidence against the use of anticoagulant low molecular weight heparin in SCLC.
Patients with lung cancer and atherosclerosis diagnosis may benefit from anti-inflammatory therapy with canakinumab.
Patients with NSCLC experienced improvements in both function and quality of life with yoga therapy.
Study results stress the importance of a multiethnic support system for patients needing to overcome communication barriers.
PanCan study effectively identified patients who eventually developed early-stage lung cancer, compared to other predictive models.